These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1234 related articles for article (PubMed ID: 26858290)

  • 41. Competing risks and time-dependent covariates.
    Cortese G; Andersen PK
    Biom J; 2010 Feb; 52(1):138-58. PubMed ID: 20029852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stagewise pseudo-value regression for time-varying effects on the cumulative incidence.
    Zöller D; Schmidtmann I; Weinmann A; Gerds TA; Binder H
    Stat Med; 2016 Mar; 35(7):1144-58. PubMed ID: 26510388
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analyses of cumulative incidence functions via non-parametric multiple imputation.
    Ruan PK; Gray RJ
    Stat Med; 2008 Nov; 27(27):5709-24. PubMed ID: 18712779
    [TBL] [Abstract][Full Text] [Related]  

  • 44. causalCmprsk: An R package for nonparametric and Cox-based estimation of average treatment effects in competing risks data.
    Vakulenko-Lagun B; Magdamo C; Charpignon ML; Zheng B; Albers MW; Das S
    Comput Methods Programs Biomed; 2023 Dec; 242():107819. PubMed ID: 37774426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluating cardiovascular mortality in type 2 diabetes patients: an analysis based on competing risks Markov chains and additive regression models.
    Rosato R; Ciccone G; Bo S; Pagano GF; Merletti F; Gregori D
    J Eval Clin Pract; 2007 Jun; 13(3):422-8. PubMed ID: 17518809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A competing-risks nomogram for sarcoma-specific death following local recurrence.
    Kattan MW; Heller G; Brennan MF
    Stat Med; 2003 Nov; 22(22):3515-25. PubMed ID: 14601016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Competing risks analyses: objectives and approaches.
    Wolbers M; Koller MT; Stel VS; Schaer B; Jager KJ; Leffondré K; Heinze G
    Eur Heart J; 2014 Nov; 35(42):2936-41. PubMed ID: 24711436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peritonitis-free survival in peritoneal dialysis: an update taking competing risks into account.
    Evans DW; Ryckelynck JP; Fabre E; Verger C
    Nephrol Dial Transplant; 2010 Jul; 25(7):2315-22. PubMed ID: 20103502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meta-analysis for aggregated survival data with competing risks: a parametric approach using cumulative incidence functions.
    Bonofiglio F; Beyersmann J; Schumacher M; Koller M; Schwarzer G
    Res Synth Methods; 2016 Sep; 7(3):282-93. PubMed ID: 26387882
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use and interpretation of competing risks regression models.
    Dignam JJ; Zhang Q; Kocherginsky M
    Clin Cancer Res; 2012 Apr; 18(8):2301-8. PubMed ID: 22282466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Current peritoneal dialysis compared with haemodialysis: medium-term survival analysis of incident dialysis patients in the Canary Islands in recent years].
    Rufino JM; García C; Vega N; Macía M; Hernández D; Rodríguez A; Maceira B; Lorenzo V
    Nefrologia; 2011; 31(2):174-84. PubMed ID: 21461011
    [TBL] [Abstract][Full Text] [Related]  

  • 52. When do we need competing risks methods for survival analysis in nephrology?
    Noordzij M; Leffondré K; van Stralen KJ; Zoccali C; Dekker FW; Jager KJ
    Nephrol Dial Transplant; 2013 Nov; 28(11):2670-7. PubMed ID: 23975843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vertical modelling: Analysis of competing risks data with missing causes of failure.
    Nicolaie MA; van Houwelingen HC; Putter H
    Stat Methods Med Res; 2015 Dec; 24(6):891-908. PubMed ID: 22179822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Relationship between metabolic diseases and all-cause and cardiovascular death in an elderly male population during a 15-year follow-up].
    Sun B; Shao Y; Li J; Tian H; Li C
    Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(12):913-8. PubMed ID: 24854911
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Considerations for analysis of time-to-event outcomes subject to competing risks in veterinary clinical studies.
    Oyama MA; Shaw PA; Ellenberg SS
    J Vet Cardiol; 2018 Jun; 20(3):143-153. PubMed ID: 29680637
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimation and comparison of cumulative incidences of biliary self-expandable metallic stent dysfunction accounting for competing risks.
    Hamada T; Nakai Y; Isayama H; Togawa O; Kogure H; Kawakubo K; Tsujino T; Sasahira N; Hirano K; Yamamoto N; Ito Y; Sasaki T; Mizuno S; Toda N; Tada M; Koike K
    Dig Endosc; 2014 Mar; 26(2):270-5. PubMed ID: 23650933
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sample size calculations in the presence of competing risks.
    Latouche A; Porcher R
    Stat Med; 2007 Dec; 26(30):5370-80. PubMed ID: 17955563
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simulating competing risks data in survival analysis.
    Beyersmann J; Latouche A; Buchholz A; Schumacher M
    Stat Med; 2009 Mar; 28(6):956-71. PubMed ID: 19125387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct likelihood inference and sensitivity analysis for competing risks regression with missing causes of failure.
    Moreno-Betancur M; Rey G; Latouche A
    Biometrics; 2015 Jun; 71(2):498-507. PubMed ID: 25761785
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic models with competing risks: methods and application to coronary risk prediction.
    Wolbers M; Koller MT; Witteman JC; Steyerberg EW
    Epidemiology; 2009 Jul; 20(4):555-61. PubMed ID: 19367167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.